Gambierdiscus species are marine dinoflagellates producers of toxins causative of a widespread human illness known as Ciguatera Fish Poisoning (CFP) which comprises gastrointestinal, neurological, and cardiovascular symptoms. Blooms of these dinoflagellates have expanded worldwide reaching even European coasts. In fact, the presence of Gambierdiscus species and the related toxins and CFP intoxications have been repetitively identified in Europe during the last decades, especially in the Canary Islands [1,2] and Madeira [3]. Besides ciguatoxins, which can cause long term neurological sequela in humans as a consequence of their permanent activation voltage-gated sodium channels [4-6], the structure of an additional ciguatoxin-related toxin named 44-methylgambierone (MTX3) has been recently elucidated [7]. Initial studies on the biological activity of 44-methylgambierone described an effect similar to that of the synthetic ciguatoxin CTX3C although of much lower potency [7]. With the aim of further explore the relative toxicities and activities of these compounds additional experiments were performed. First, the neurotoxic effect of CTX3C and MTX3 was evaluated using a human neuronal cell model based on the incubation of SH-SY5Y with ouabain and veratridine together with ciguatoxin or ciguatoxin-like compounds to evaluate their in vitro toxic potency [8]. Our data illustrate that CTX3C aggravated the ouabain and veratridine neurotoxicity but 44-methylgambierone did not resembled this effect. Additionally, while CTX3C at nanomolar concentrations hyperpolarized the activation of voltage-gated sodium channels and decreased current amplitude, 44-methylgambierone did not affect sodium currents. Moreover, oral chronic toxicity studies using daily CTX3 concentrations of 10, 32 and 100 ng/kg or MTX3 at 550 or 1760 ng/kg and an observation period of 28 days did not shown behavioral or biochemical alterations during treatment. Based on in vitro and in vivo results, the ciguatoxin-related compound 44-methylgambierone, recently identified in Gambierdiscus extracts, is less potent than CTX3C and thus indicates that the effect on human CFP symptoms may also be minor.
References